GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CLS Holdings USA Inc (XCNQ:CLSH) » Definitions » Other Operating Expense

CLS Holdings USA (XCNQ:CLSH) Other Operating Expense : C$-1.25 Mil (TTM As of Feb. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CLS Holdings USA Other Operating Expense?

CLS Holdings USA's Other Operating Expense for the three months ended in Feb. 2024 was C$-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Feb. 2024 was C$-1.25 Mil.

CLS Holdings USA's quarterly Other Operating Expense increased from Aug. 2023 (C$-1.25 Mil) to Nov. 2023 (C$0.00 Mil) but then declined from Nov. 2023 (C$0.00 Mil) to Feb. 2024 (C$-0.00 Mil).


CLS Holdings USA Other Operating Expense Historical Data

The historical data trend for CLS Holdings USA's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CLS Holdings USA Other Operating Expense Chart

CLS Holdings USA Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CLS Holdings USA Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1.25 - -

CLS Holdings USA Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CLS Holdings USA Other Operating Expense Related Terms

Thank you for viewing the detailed overview of CLS Holdings USA's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


CLS Holdings USA (XCNQ:CLSH) Business Description

Traded in Other Exchanges
Address
1800 Industrial Road, Suite 100, Las Vegas, NV, USA, 89102
CLS Holdings USA Inc is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada and plans to expand to other states. CLS stands for Cannabis Life Sciences in recognition of the company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services. The company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products.